About GenoMethods
GenoMethods is built around one editorial conviction: the breakthroughs that matter most in biotechnology can be explained clearly without making them shallow.
What GenoMethods is
We are a global English-language publication covering biotechnology, bioinformatics, artificial intelligence in biology, genomics, diagnostics, drug discovery, gene editing, cellular engineering, synthetic biology and longevity science. We write for broad readers and for scientists who want context outside their own subfield.
Our work combines newsroom judgement with method-level explanation. We separate discovery from validation, preprint from peer-reviewed evidence, laboratory promise from clinical outcome and commercial narrative from measurable progress.
How we began
GenoMethods began in 2002 as an online resource repository for artificial intelligence and machine learning methods in bioinformatics. The public launch connected the project to a special issue on methods in functional genomics and to the work of Paola Sebastiani, Marco Ramoni and Isaac Kohane.
The early project developed around the problems that defined post-genome-era biology: how to cluster expression dynamics, select informative genetic markers, reason under uncertainty and make advanced computational methods available to researchers.
People and institutions in the record
The visible founding record names Paola Sebastiani of the University of Massachusetts Amherst, Marco Ramoni of Harvard Medical School and Isaac Kohane of Harvard Medical School as central figures in the original public identity of the project. The software traces also connect the work to Harvard, Boston Children’s Hospital and the computational biology community that shaped early biomedical informatics.
We preserve those names because they belong to the public history of GenoMethods. The renewed publication carries forward the same method-oriented editorial line: computational biology, evidence and open scientific explanation.
The subjects that shaped the archive
The archive is associated with CAGED for cluster analysis of gene expression dynamics, BEST for minimal haplotype tagging, BADGE for Bayesian analysis of differential expression and SCA for Bayesian-network work in genomics. Those resources mark a period when bioinformatics moved from niche computational practice into an essential layer of biomedical research.
They also explain our current editorial focus. Modern biotechnology now runs on the same questions at larger scale: which data are trustworthy, which model is valid, which biological signal matters, which tool can be reproduced and which claim survives contact with clinical evidence.
Why the publication returned in 2026
By 2026, AI in biology, CRISPR medicine, spatial omics, foundation models, cellular therapies and longevity science had made the old GenoMethods question newly public. Readers outside specialist labs now need to understand methods, not only headlines.
The return of GenoMethods is therefore not a change of subject. It is a wider expression of the same editorial discipline, applied to the companies, products, trials, databases and discoveries that define biotechnology today.
How we work
We write from the position of a specialist publisher with a public audience. Every major article identifies the evidence base, explains the method, names the limits and gives readers a clear path to primary sources, regulatory documents, datasets or technical documentation.
Our style is authorial, analytical and accountable. We prefer careful explanation to volume, durable reference pages to disposable summaries and plain English to jargon that hides weak reasoning.